FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hall Susan</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol Endo International plc [ ENDP ]								(Ch	eck all app Direc	olicable) ctor	g Person(s) to I	Owner		
(Last) (First) (Middle) C/O ENDO INTERNATIONAL PLC MINERVA HOUSE, SIMMONSCOURT ROAD					3. Date of Earliest Transaction (Month/Day/Year) 11/11/2015									belo	,	Other (specify below)  pal Head of R&D		
(Street) BALLSE DUBLIN (City)	BRIDGE, L2 00000 (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	) <mark>X</mark> Forn Forn	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person			
		Tabl	e I - No	n-Deriva	ative	Sec	curitie	s Acc	quired,	Dis	posed o	f, or	Bene	ficial	y Own	ed		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da			Execution Dat		n Date,	Transaction Disp Code (Instr. 5)		Disposed	Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 D)			Secur Benef	icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A	) or )	Price	Trans	action(s) 3 and 4)		(Instr. 4)
Ordinary Shares 11/11/2				2015		P		1,000		A	\$ <mark>55.3</mark>	5	2,666	D				
Stock Incentive Plan Performance Shares <sup>(1)</sup> 11/11/2				2015		A		1,000(2)		A	(3)	13	3,740(4)	D				
Stock Incentive Plan Restricted Stock Units (RSU) <sup>(5)</sup>														7	,515 <sup>(5)</sup>	D		
		Та									sed of, onvertib				Owned			
1. Title of Derivative Security (Instr. 3)	erivative conversion or Exercise (Month/Day/Year) str. 3) Price of Derivative Security  Date (Month/Day/Year) (Month/Day/Year)  Execution Date, if any (Month/Day/Year)		4. Transac Code (Ir 8)	nstr.	5. Nu of Deriv Secul Acqu (A) on Dispc of (D) (Instrand 5	6. Date Expiratic (Month/D	on Dat		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		unt	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

## **Explanation of Responses:**

- 1. The performance shares vest upon the Company achieving certain shareholder return targets over a cumulative 3-year period.
- 2. Represents the target number of shares issuable upon achievement of a certain shareholder return target over a cumulative 3-year period, as determined by the Registrant's Board of Directors at the end of such three-year period. The ultimate number of shares issued may be the target number or zero, depending on the Registrant's attainment of the shareholder return target over the period.
- 3. Pursuant to the Endo International plc Matched Performance Share Unit Program, the Registrant matched Ms. Hall's open market purchases of ordinary shares, subject to certain limitations, which occurred on November 11, 2015, as reported above. These securities were granted to Ms. Hall in consideration of her services as the Executive Vice President, Chief Scientific Officer, Global Head of R&D of Endo International plc.
- 4. Represents the cumulative target quantity of shares issuable with respect to all 2010 and 2015 Stock Incentive Plan performance shares outstanding. The cumulative total is the combination of the target payouts for the current grant and all past grants made under the 2010 Stock Incentive Plan and the 2015 Stock Incentive Plan and still outstanding, which are subject to a range of payouts depending on the achievement of certain performance metrics as described herein for the current grant and as previously disclosed for all other performance share grants.
- 5. Subject to time-based vesting, each restricted stock automatically converts into one (1) ordinary share of Endo International plc.

## Remarks:

/s/ Matthew J. Maletta, by Power of Attorney

11/12/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these present that the undersigned hereby makes, constitutes and appoints Matthew J. Maletta, Orla Dunlea, Daniel A. Rudio, Dan McCall and Justin Dailey as the undersigned's true and lawful attorneys-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of each of the undersigned to:

- (1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of Endo International plc, an Irish public limited company (the "Company"), with the United States Securities and Exchange Commission, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act");
- (2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and
- (3) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

- (1) this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;
- (2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;
- (3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and
- (4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney.

This Power of Attorney shall remain in full force and effect with respect to each undersigned until revoked by such undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of May 2015.

SIGNATURE TITLE

/s/ Susan T. Hall EVP, Chief Scientific Officer & Global Head of R&D and Quality

NAME: Susan T. Hall

STATE OF Pennsylvania: COUNTY OF Chester:

On this 4th day of May 2015, the above-named individual personally appeared before me, and acknowledged that he executed the foregoing instrument for the purposes therein contained.

IN WITNESS WHEREOF, I have hereunto set my hand and official seal.

/s/ Susan E. Dear Notary Public

Commonwealth of Pennsylvania Notarial Seal Susan E. Dear, Notary Public Bethel Twp., Delaware County My Commission Expires January 8, 2017